Tuberous Sclerosis Alliance salutes FDA approval of Afinitor® DISPERZ (everolimus) as the first adjunctive treatment approved in US for patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures

TS Alliance Logo. (PRNewsFoto/Tuberous Sclerosis Alliance) (PRNewsfoto/Tuberous Sclerosis Alliance)SILVER SPRING, Md., April 10, 2018 /PRNewswire-USNewswire/ — Today, the Tuberous Sclerosis Alliance (TS Alliance) is pleased to share that the U.S. Food and Drug Administration has approved the drug Afinitor, manufactured by Novartis Pharmaceuticals, to treat partial-onset seizures in…


About M Fund